Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
News Briefing channel feed
Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand Pharma
11 months ago
Adaptimmune’s debt financing deal; Tenaya to cut workers
11 months ago
Allogene's $110M offering; Apellis refinances
11 months ago
Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer
12 months ago
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
12 months ago
R&D
Royalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher
12 months ago
Pharming ends deal with Orchard; Seres considers cost-cutting
Last year
Lykos’ MDMA therapy to go before FDA committee; GSK expands work with BioVersys
Last year
Gates, Novo Nordisk, Wellcome foundations put $300M in global health; BioNTech stops prostate cancer study
Last year
Royalty Pharma's milestone payment to Arrowhead; Abeona's $75M offering
Last year
Context Therapeutics' $100M placement; Blueprint raises guidance for rare disease drug
Last year
Editas, BMS extend T cell deal; KalVista seeks partner for preclinical HAE program
Last year
Daré's royalty deal; Qlaris Bio raises $24M
Last year
4P-Pharma raises €15M; Oncotelic Therapeutics sells rights to cancer assets
Last year
Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit
Last year
Cerevance's $47M raise; Parexel's AI pact
Last year
Centessa's public offering; Vivoryon ends Ph2 Alzheimer’s trial
Last year
Brise raises $20M; Taro shareholder criticizes Sun Pharma deal
Last year
Ipsen, Skyhawk ink deal worth up to $1.8B; Hepion to wind down NASH trial
Last year
Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment
Last year
Biohaven’s $230M offering; Plus, three new PIPEs
Last year
Intra-Cellular aims to raise $500M; Lilly’s Prevail cuts three partnered programs
Last year
Takeda’s new deal with Kumquat; IL-2 biotech raises $55M
Last year
Mustang Bio to lay off workers; MaaT's new data for microbiome therapy
Last year
First page
Previous page
7
8
9
10
11
12
13
Next page
Last page